Skip to content
Screener

Janux Therapeutics JANX Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$7.9MBeat by $7.8M
EPS-$0.51Beat by $0.14
Revenue estimate$83.3K
EPS estimate-$0.65

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$8.0M
EPS estimate-$0.45

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$42.4M-46.1%
Net income-$31.9M-58.0%
EPS (diluted)-$0.51-45.7%

Balance sheet

See full
Cash & equivalents$52.3M-87.8%
Total debt$22.1M-3.8%
Total equity$956.8M-6.4%
Total assets$1.0B-5.6%

Cash flow

See full
Operating cash flow-$28.5M-70.7%
CapEx$106.0K+152%
Free cash flow-$28.6M-70.9%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$830.04M-73.6%
Enterprise value$799.84M-70.7%
P/S83×-213×

Profitability

See full
Operating margin-1,576.7%+3,491pp
Net margin-1,136.3%+3,297pp
FCF margin-832.8%+213,978pp

Returns & leverage

See full
Return on equity-11.5%+1.8pp
Debt / equity0×0.0×
Current ratio39×-20.2×

FAQ

When did Janux Therapeutics report Q4 2025 earnings?
Janux Therapeutics (JANX) reported Q4 2025 earnings on February 26, 2026 before market open.
What were Janux Therapeutics's Q4 2025 revenue and EPS?
Janux Therapeutics reported revenue of $7.9M and eps of $-0.51 for Q4 2025.
Did Janux Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $83.3K by $7.8M. EPS beat the consensus estimate of $-0.65 by $0.14.
How did Janux Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 41.7% from $-0.36.
Where can I find Janux Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-076627) and the 10-K periodic report (0001193125-26-076918) directly on SEC EDGAR. The filing index links above go to sec.gov.